available for iOS, Android & web
September 28, 2015
March 26, 2015
September 02, 2014
Prompted by failure of rheumatoid arthritis drug
November 09, 2012
Shares in Novo Nordisk have soared this morning after an FDA panel recommended approval of Tresiba and Ryzodeq, despite expressing concerns over possible cardiovascular risk of the ultra long-acting insulins
November 01, 2012
Novo Nordisk has posted another healthy set of figures for the third quarter, helped by strong sales of diabetes drug Victoza and its modern insulins
October 22, 2012
Recommendations from EMA advisors include rejecting Lundbeck’s Acrescent for Alzheimer’s disease, and approving Novo Nordisk's diabetes drugs Tresiba and Ryzodeg.
International Clinical Researcher of the Year 2016
Last chance to enter!
PharmaTimes 2015 Copyright | RSS Feed Subscriptions